Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

Condensed Consolidated Balance Sheets

(In thousands, except par value)

December 31, December 31,

2007 2006

Assets

Current assets:

Cash and cash equivalents $27,066 $24,301

Accounts receivable 4,689 2,319

Prepaid expenses and other current assets 2,579 2,048

Total current assets 34,334 28,668

Property and equipment, net 4,390 3,357

Goodwill 6,462 6,917

Patents, net 7,680 8,850

Other assets 196 321

Restricted cash 3,190 3,059

Total assets $56,252 $51,172

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $2,335 $1,680

Accrued expenses 4,765 10,153

Warrant liabilities 5,218 -

Other liabilities 520 366

Short-term note - 1,320

Current portion of long-term debt obligations 2,401 599

Current portion of deferred revenue 3,360 2,972

Total current liabilities 18,599 17,090

Deferred revenue, net of current portion 8,366 195

Other non-current liabilities 2,055 1,961

Long-term debt obligations, net of current

portion
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...  New Jersey Health Foundation, a not-for-profit organization that ... New Jersey , has committed $1 ... James M. Golubieski , president. Through ... an additional $500,000 will be available for awards of ... projects that demonstrate exciting potential and may lead to ...
(Date:3/30/2015)... March 30, 2015 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a commercial focus on China ... Administration (CFDA) has approved the Company,s application to conduct ... cell carcinoma (OCCC) patients for its proprietary drug candidate ...
(Date:3/30/2015)... Md. , March 30, 2015    ... leader in synthetic biology, and Merck Serono, the ... Germany , today announced an exclusive strategic ... Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This ... develop innovative therapies that modulate the immune system,s ...
(Date:3/30/2015)... USA (PRWEB) March 29, 2015 A ... the United States and plenary talks by four leading ... SPIE Optics + Optoelectronics next month in Prague, ... presentations in 17 conferences alongside a two-day exhibition. Sponsored ... photonics , the event will run 13-16 April in ...
Breaking Biology Technology:New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3
... even the resources of the world,s largest industrialized nations, scientists ... to find solutions. , Mark Shannon of the University of ... water resource research to address this crisis in a review ... "As dire as the growing problems are with a lack ...
... Blacksburg, Va. -- The ubiquity of mineral nanoparticles in ... intriguing properties provide Earth scientists with another dimension in ... team of scientists from seven universities in a review ... Nanominerals, Mineral Nanoparticles, and Earth Chemistry. , The way ...
... March 20 Scientists at the,Bio-Communications Research ... for,the Improvement of Human Functioning International (CIHFI), ... about its recent stem cell,discovery. The scientific ... stem cell population" received BioMed Central,s,Research Article ...
Cached Biology Technology:Countering an approaching water crisis 2Nanoscience will change the way we think about the world 2Nanoscience will change the way we think about the world 3Nanoscience will change the way we think about the world 4Nanoscience will change the way we think about the world 5Medical Research Award Goes to Adult Stem Cell Scientists at a Kansas Not-for-Profit Organization 2
(Date:3/23/2015)... SoundView Technology Group issues a new research update following the ... wallet. SoundView was one of the selected user groups to provide ... in multiple scenarios and outlets. Soundview shares ... both debit and credit card payments.  Soundview ... meets their plans in 2015, it would push our IV ...
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... March 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... one of the products featured in 2015 "I Want ... 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 International ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... a pack of lionesses chasing down a lonely gazelle ... bacteria. Working with colleagues at Caltech, Stanford and ... has developed a living system using genetically altered bacteria ... the population levels of prey influence the levels of ...
... DIEGO Genetic variations ensure that no two people ... have the tools and the knowledge to predict how ... and effective treatment. At the 2008 Annual Meeting of ... 16, researchers present data on new biomarkers that can ...
... 1:00 p.m. ET) Research published in Nature Chemical Biology ... pathway, termed necroptosis, all target and inhibit RIP1 kinase, ... by trauma such as a heart attack or stroke, ... damage contributing to death or long-term disability. The findings ...
Cached Biology News:Novel living system recreates predator-prey interaction 2Novel living system recreates predator-prey interaction 3Biomarkers allow doctors to match therapy to patient 2Biomarkers allow doctors to match therapy to patient 3Biomarkers allow doctors to match therapy to patient 4Biomarkers allow doctors to match therapy to patient 5Biomarkers allow doctors to match therapy to patient 6Biomarkers allow doctors to match therapy to patient 7Stopping unwanted cell death: Implications for drug discovery 2Stopping unwanted cell death: Implications for drug discovery 3
... Science LAS-3000 imaging system combines new ... user interface, providing significantly improved system ... modularities. The LAS-3000 provides significantly improved ... of applications including: fluorescence, chemifluorescence, chemiluminescence, ...
The LAS-3000 imaging system combines new CCD camera technology with a simplified user interface to provide significantly improved system sensitivity with a wide range of modularities. This system is...
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
Biology Products: